
Product data sheet



r				
MedKoo Cat#: 330218				
Name: (R)-Carisbamate				
CAS#: 194085-74-0 (R-isomer)				
Chemical Formula: C ₉ H ₁₀ ClNO ₃				
Exact Mass: 215.0349				
Molecular Weight: 215.633				
Product supplied as:	Powder			
Purity (by HPLC):	\geq 98%			
Shipping conditions	Ambient temperature			
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.			
-	In solvent: -80°C 3 months; -20°C 2 weeks.			



1. Product description:

(R)-Carisbamate is the R-isomer of Carisbamate. Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

5. Solubility uuu				
Solvent	Max Conc. mg/mL	Max Conc. mM		
DMSO	TBD	TBD		

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.64 mL	23.19 mL	46.38 mL
5 mM	0.93 mL	4.64 mL	9.28 mL
10 mM	0.46 mL	2.32 mL	4.64 mL
50 mM	0.09 mL	0.46 mL	0.93 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

TBD

In vivo study

1. Ono T, Moshé SL, Galanopoulou AS. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. Epilepsia. 2011 Sep;52(9):1678-84. doi: 10.1111/j.1528-1167.2011.03173.x. Epub 2011 Jul 19. PMID: 21770922; PMCID: PMC3169712.

7. Bioactivity

Biological target:

Carisbamate is a novel neurotherapeutic drug.

In vitro activity

TBD

Product data sheet



In vivo activity

The efficacy of carisbamate was tested to suppress spasms in the multiple-hit rat model of SIS. Sprague-Dawley rats received right intracerebral infusions of doxorubicin and lipopolysaccharide at postnatal day 3 (PN3) and intraperitoneal p-chlorophenylalanine at PN5. A single intraperitoneal injection of carisbamate was administered at PN4. Carisbamate acutely reduced both behavioral spasms (CRS-30 and CRS-60 groups only) and electroclinical spasms during the first 2-3 postinjection hours, without detectable toxicity or mortality. The findings provide preclinical evidence that carisbamate displays acute anticonvulsive effect on spasms through a sodium channel-independent mechanism. Because spasms in the multiple-hit rat model are refractory to ACTH and transiently sensitive to vigabatrin, carisbamate may constitute a candidate new therapy for SIS, including the ACTH-refractory spasms.

Reference: Epilepsia. 2011 Sep;52(9):1678-84. https://pubmed.ncbi.nlm.nih.gov/21770922/

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.